盲人复明，太了不起了。 这可能是2025年最低调但又最闪亮的科技进展了。 Nature最新刊登了新研究进展，人工视觉技术刚刚帮助一位70岁奶奶重获光明。 在失明之前，我是个狂热的书虫，我想把它找回来。 70岁的Sheila Irvine（希拉·欧文）最大的愿望是能够再次阅读，而就在最近她的愿望成真了。 原因来自于一项世界首创的人工视觉研究PRIMA。 其背后带队的还是当年和马斯克一起创办Neuralink的联合创始人，现在自己创业，做的还是视网膜植入物。 厚度只有一根头发丝大小，却能够让80%的患者视力得到显著改善，并且能够顺利阅读字母、数字和单词。 在参与实验之前，希拉是这样描述自己的： 我的眼睛就像有两个黑色的椎间盘，外面扭曲了。 故事的开始还要回到15年前，那是她第一次发现自己开车不受控制，一直在撞击人行道，当她走进医院后，她被确诊患有年龄相关性黄斑变性 （AMD）。 对此，论文主要作者Frank Holz表示： 该研究首次证明人工视觉可以恢复患者的功能性中央视力，为失明者带来了希望。 而对于患者本身及其家人，或许这将是人至暮年，一次宝贵的再次见面的机会： 失明15年，终于重获光明的她 这是一种老年人的 ...

Core Viewpoint - The article highlights a groundbreaking advancement in artificial vision technology, specifically the PRIMA retinal implant, which has successfully restored functional central vision in patients suffering from age-related macular degeneration (AMD) [2][10][24]. Group 1: Technology Overview - The PRIMA system is a world-first artificial vision research project that utilizes a retinal implant to restore vision by acting as a substitute for light-sensitive cells [6][25]. - The device is a small photovoltaic retinal implant (2mm x 2mm x 30μm) that works wirelessly, powered by light captured through special glasses equipped with a camera [27]. - The system has shown promising results, with 84% of participants recovering functional central vision and 80% achieving a significant improvement in visual acuity [30]. Group 2: Patient Experience - Sheila Irvine, a 70-year-old participant, regained her vision after 15 years of blindness due to AMD, fulfilling her lifelong desire to read again [5][11]. - Prior to the experiment, Sheila described her vision as severely impaired, likening her eyes to "two black discs" [11]. - After the surgery and rehabilitation, she was able to recognize small text, demonstrating the potential of the PRIMA system to significantly enhance quality of life for patients [15][30]. Group 3: Clinical Trials and Results - The clinical trial involved 38 patients across 17 clinical sites in five countries, with evaluations conducted at 6 and 12 months post-implantation [29]. - The results indicated an average improvement of 25.5 letters (approximately 5 lines) in visual acuity for participants [30]. - While some patients experienced temporary adverse reactions, 95% of these symptoms resolved within two months, and there was no significant decline in peripheral vision [32]. Group 4: Future Prospects - The PRIMA system is currently undergoing regulatory approval processes in Europe and the U.S., with plans for a commercial launch in the near future [35]. - Researchers are also developing next-generation implants and glasses to enhance visual performance, aiming for smaller pixels and color vision capabilities [38]. - The project is seen as a significant step towards making "artificial vision" a reality, akin to the advancements made with cochlear implants for hearing [49].